ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,575.90
-1.39%
S&P ASX All Technology
2,970.40
-1.25%
Brent Oil
88.165
0.00%
US Dollar vs AUD
1.53139
0.00%
Bitcoin
63,209.17
-0.83%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Maxcyte Inc (MXCT)

  7. Maxcyte Inc (MXCT) News

MXCT Maxcyte Inc

295.00
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Maxcyte Inc MXCT London Ordinary Share
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 295.00 17:00:00
Open Price Low Price High Price Close Price Previous Close
295.00 295.00 295.00 295.00 295.00
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Recent News

Date Time Source Heading
10/4/202422:05GLOBEMaxCyte to Report First Quarter 2024 Financial Results on..
10/4/202422:05UK RNSMaxCyte, Inc. Notice of Results
03/4/202417:00UK RNSMaxCyte, Inc. Total Voting Rights and Block Listing Return
03/4/202401:19ALNCNewsTRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian..
02/4/202423:05UK RNSMaxCyte, Inc. Signing of Strategic Platform License
02/4/202423:05GLOBEMaxCyte Signs Strategic Platform License with Be Biopharma..
02/4/202417:00UK RNSMaxCyte, Inc. Exercise of options and PDMR dealing
20/3/202421:16UK RNSMaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR..
20/3/202421:05UK RNSMaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR..
13/3/202422:54ALNCNewsIN BRIEF: MaxCyte loss widens in 2023 as core revenue..
13/3/202418:05UK RNSMaxCyte, Inc. Filing of form 10-K for FY ended December 31,..
13/3/202418:00UK RNSMaxCyte, Inc. Reports Q4 & FY 2023 Financial Results
13/3/202407:05UKREGMaxCyte Reports Fourth Quarter and Full Year 2023 Financial..
06/3/202419:58UK RNSMaxCyte, Inc. TR-1: Notification of major holdings
06/3/202407:43ALNCNewsEARNINGS: dotdigital eyes rosy future; Beeks Financial turns..
05/3/202418:00UK RNSMaxCyte, Inc. Preliminary FY Results & 2024 Guidance
05/3/202408:05UKREGMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023..
02/3/202404:57UK RNSMaxCyte, Inc. Total Voting Rights
29/2/202420:21UK RNSMaxCyte, Inc. Exercise of options and PDMR dealing
26/2/202418:00UK RNSMaxCyte, Inc. TR-1: Notification of major holdings
10/2/202400:05UK RNSMaxCyte, Inc. Notice of Results
10/2/202400:05UKREGMaxCyte to Report Fourth Quarter and Full Year 2023..
01/2/202420:24UK RNSMaxCyte, Inc. Total Voting Rights
31/1/202418:00UK RNSMaxCyte, Inc. Director/PDMR Shareholding
31/1/202401:29UK RNSMaxCyte, Inc. Holding(s) in Company
31/1/202400:58ALNCNewsIN BRIEF: MaxCyte signs licencing deal with cell therapy..
31/1/202400:05UK RNSMaxCyte, Inc. Signing of Strategic Platform License
31/1/202400:05UKREGMaxCyte and Wugen Sign Strategic Platform License to..
30/1/202404:56ALNCNewsIN BRIEF: MaxCyte chief scientific officer leaves firm
30/1/202403:52UK RNSMaxCyte, Inc. TR-1: Notification of major holdings
29/1/202418:00UK RNSMaxCyte, Inc. Filing of Form 8-K
24/1/202405:39ALNCNewsTRADING UPDATES: Esken's Southend Airport faces further..
24/1/202400:05UKREGMaxCyte, Inc. Signing of Strategic Platform License
24/1/202400:05GLOBEMaxCyte Signs Strategic Platform License with Imugene to..
09/1/202423:18ALNCNewsMaxCyte's strategic platform licences redeem otherwise..
09/1/202418:00UKREGMaxCyte, Inc. Preliminary Unaudited Q4 and FY 2023 Results
09/1/202408:05GLOBEMaxCyte Announces Preliminary Unaudited Fourth Quarter and..
05/1/202418:00UKREGMaxCyte, Inc. Grant of Options and PDMR Dealing
04/1/202401:04ALNCNewsMaxCyte teams with Singapore-based Lion to support TCR-T..
04/1/202400:05GLOBEMaxCyte and Lion TCR form Partnership to Support Global..
04/1/202400:05UKREGMaxCyte, Inc. Signing of Strategic Platform License
02/1/202420:23UKREGMaxCyte, Inc. Total Voting Rights
02/1/202418:00GLOBEMaxCyte Confirms Appointment of Maher Masoud as President,..
02/1/202418:00UKREGMaxCyte, Inc. Confirmation of Board change
29/12/202318:00UKREGMaxCyte, Inc. Exercise of options and PDMR dealing
13/12/202302:56ALNCNewsTRADING UPDATES: Technology Minerals identifies lithium at..
12/12/202318:00UKREGMaxCyte, Inc. CEO Transition and Revenue Guidance Update
12/12/202308:05GLOBEMaxCyte Announces CEO Transition and Updates Revenue..
07/12/202320:50UKREGMaxCyte, Inc. Exercise of options and PDMR dealing
04/12/202318:00UKREGMaxCyte, Inc. Exercise of options and PDMR dealing

Your Recent History

LSE
MXCT
Maxcyte
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved